Risk assessment for estradiol topical medications concluded

Germany's Federal Institute for Drugs and Medical Devices (BfArM) has finalized a European risk assessment concerning estradiol-containing medications intended for topical application, including use on the vulva. The procedure was initiated by Germany due to concerns about potential systemic adverse effects from high concentrations of estradiol when applied topically.

The risk assessment has resulted in significant changes to the product information for affected medications. In Germany, this specifically affects Linoladiol N® for intravaginal use and Linoladiol HN® for application to the external female genital area.

According to the BfArM's decision, effective from January 15, 2015, only medications with revised package inserts can be placed on the market. Additionally, the 100g pack size for Linoladiol N® is to be discontinued.

The manufacturer has one month to appeal the decision. As of the publication date, there was no information available regarding whether the marketing authorization holder would lodge an appeal, nor any coordinated recall announcements with the competent authorities.